Rare Incidence of Multisystem Inflammatory Syndrome in Vaccinated Children: Vaccine Recommendations
Multisystem inflammatory syndrome is rare in vaccinated children, supporting COVID-19 vaccination recommendations for everyone aged 5 and older in the United States to protect against severe illness and complications associated with SARS-CoV-2 infection.
September 2022
FDA Endorses Pfizer Booster Vaccine for Children 12-15 Years Old: Expanded Recommendations
The FDA endorses the Pfizer booster vaccine for children aged 12-15 years old and authorizes an additional dose for immunocompromised children aged 5-11 years old, alongside shortened intervals for booster doses, aiming to enhance vaccine coverage and protection against COVID-19 in pediatric populations.
September 2022
WHO Outlook on Ending the Acute Phase of the Pandemic
The WHO considers it feasible to end the acute phase of the COVID-19 pandemic in 2022 but emphasizes the importance of continued vigilance, vaccination efforts, and public health measures to prevent resurgence and control the spread of SARS-CoV-2.
September 2022
Airborne Transmission Risk of COVID-19: Practical Indicators and Mitigation Strategies
Practical indicators of airborne transmission risk in shared indoor environments provide valuable insights for implementing effective mitigation strategies to reduce the spread of COVID-19 and protect public health in community settings.
September 2022
Reduced Severity of COVID-19 in Fully Vaccinated Individuals: Comparative Analysis
COVID-19 is less severe in fully vaccinated individuals, with lower rates of mechanical ventilation and death observed among vaccinated compared to unvaccinated individuals, underscoring the protective efficacy of vaccination against severe disease outcomes in coronavirus infection.
September 2022
Human Challenge Study with SARS-CoV-2: Exploring Infection Dynamics
The first human challenge study with SARS-CoV-2 investigates the effects of viral infection in volunteers, providing valuable insights into the pathophysiology, immune response, and clinical manifestations of COVID-19, and facilitating the development of novel therapeutics and vaccines.
September 2022
WHO Cautions Against Premature Declarations of Victory over COVID-19
The WHO cautions against premature declarations of victory over COVID-19 amid lifting of restrictions in some countries, emphasizing the importance of continued vigilance and adherence to public health measures to prevent resurgence and control the spread of SARS-CoV-2.
September 2022
Hyperimmune Serum in Hospitalized COVID-19 Patients: Clinical Trial Outcomes
Hyperimmune serum therapy does not improve clinical outcomes in hospitalized COVID-19 patients, as demonstrated by a NIH trial comparing HIVIG plus remdesivir to remdesivir alone, highlighting the need for effective antiviral therapies in the management of severe COVID-19.
September 2022
Reduced Intensive Care Needs in Vaccinated Individuals: Cedars-Sinai and CDC Study
A new study from Cedars-Sinai and the CDC demonstrates that vaccinated individuals have reduced need for intensive care during surges of the Omicron and Delta variants, highlighting the effectiveness of vaccination in preventing severe COVID-19 outcomes.
September 2022
Urgent Call for Global Vaccine Action against COVID-19: Addressing Misinformation
Global efforts to combat COVID-19 must prioritize vaccine distribution and address misinformation to ensure equitable access to vaccines and control the spread of the virus, emphasizing the critical role of international cooperation and public health advocacy.
September 2022
